JP2004531473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004531473A5 JP2004531473A5 JP2002556173A JP2002556173A JP2004531473A5 JP 2004531473 A5 JP2004531473 A5 JP 2004531473A5 JP 2002556173 A JP2002556173 A JP 2002556173A JP 2002556173 A JP2002556173 A JP 2002556173A JP 2004531473 A5 JP2004531473 A5 JP 2004531473A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- phenyl
- methyl
- alkyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 —OR 7 Chemical group 0.000 claims 308
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 40
- 125000000623 heterocyclic group Chemical group 0.000 claims 28
- 125000001424 substituent group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000005843 halogen group Chemical group 0.000 claims 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 14
- 125000004076 pyridyl group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000004043 oxo group Chemical group O=* 0.000 claims 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 9
- 125000002883 imidazolyl group Chemical group 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 7
- 125000001544 thienyl group Chemical group 0.000 claims 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 6
- 125000002757 morpholinyl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims 6
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000002541 furyl group Chemical group 0.000 claims 5
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000005956 isoquinolyl group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 4
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 3
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- CBCROIPJZHJWRD-UHFFFAOYSA-N 6-chloro-n-(3-fluoro-4-methylphenyl)-2-[(4-methoxyphenyl)methylamino]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC1=NC(Cl)=CC=C1C(=O)NC1=CC=C(C)C(F)=C1 CBCROIPJZHJWRD-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 2
- 125000003418 alkyl amino alkoxy group Chemical group 0.000 claims 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical group NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims 1
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 claims 1
- KFVKYZSMMMDKRE-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-ylmethylamino)-n-(4-phenoxyphenyl)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=C3OCOC3=CC=2)C=1C(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 KFVKYZSMMMDKRE-UHFFFAOYSA-N 0.000 claims 1
- ODIUWSGXFVVAKM-UHFFFAOYSA-N 2-(benzylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CC=CC=2)=C1 ODIUWSGXFVVAKM-UHFFFAOYSA-N 0.000 claims 1
- SYUKLOYZNHCGBC-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC1=CC=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1F SYUKLOYZNHCGBC-UHFFFAOYSA-N 0.000 claims 1
- DYNPEMXFFWJLMJ-UHFFFAOYSA-N 2-[(2,4-difluorophenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1CNC1=NC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 DYNPEMXFFWJLMJ-UHFFFAOYSA-N 0.000 claims 1
- PWMUDLQOCMEUCU-UHFFFAOYSA-N 2-[(2,6-difluorophenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC1=CC=CC(F)=C1CNC1=NC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 PWMUDLQOCMEUCU-UHFFFAOYSA-N 0.000 claims 1
- KSQCHVLQEUNDEM-UHFFFAOYSA-N 2-[(2-fluorophenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC1=CC=CC=C1CNC1=NC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 KSQCHVLQEUNDEM-UHFFFAOYSA-N 0.000 claims 1
- NRZKLXGUIKBKLJ-UHFFFAOYSA-N 2-[(3,4-difluorophenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC1=NC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 NRZKLXGUIKBKLJ-UHFFFAOYSA-N 0.000 claims 1
- JACJEBUBJKACMQ-UHFFFAOYSA-N 2-[(3,4-dimethoxyphenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CNC1=NC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 JACJEBUBJKACMQ-UHFFFAOYSA-N 0.000 claims 1
- GCLWSEBLZMMEHH-UHFFFAOYSA-N 2-[(3-bromophenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=C(Br)C=CC=2)=C1 GCLWSEBLZMMEHH-UHFFFAOYSA-N 0.000 claims 1
- HCSKCSKMJMETRI-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=C(Cl)C=CC=2)=C1 HCSKCSKMJMETRI-UHFFFAOYSA-N 0.000 claims 1
- RBJFLTHSDVTGBL-UHFFFAOYSA-N 2-[(3-fluorophenyl)methylamino]-n-(4-phenoxyphenyl)pyridine-3-carboxamide Chemical compound FC1=CC=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 RBJFLTHSDVTGBL-UHFFFAOYSA-N 0.000 claims 1
- ZUGLOPTZPUVQOK-UHFFFAOYSA-N 2-[(3-methoxyphenyl)methylamino]-n-(4-propan-2-ylphenyl)pyridine-3-carboxamide Chemical compound COC1=CC=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)C)=C1 ZUGLOPTZPUVQOK-UHFFFAOYSA-N 0.000 claims 1
- NQIKQTJNGDKTGP-UHFFFAOYSA-N 2-[(4-bromophenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CC(Br)=CC=2)=C1 NQIKQTJNGDKTGP-UHFFFAOYSA-N 0.000 claims 1
- COWAPRLHHAXZLW-UHFFFAOYSA-N 2-[(4-chlorophenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CC(Cl)=CC=2)=C1 COWAPRLHHAXZLW-UHFFFAOYSA-N 0.000 claims 1
- BFHOOZSXILGZME-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]-n-(4-propan-2-ylphenyl)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(F)C=C1 BFHOOZSXILGZME-UHFFFAOYSA-N 0.000 claims 1
- ZILBQSNRPDGJDC-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]-n-[3-(2-pyrrolidin-1-ylethoxy)-4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CNC1=NC=CC=C1C(=O)NC1=CC=C(C(F)(F)F)C(OCCN2CCCC2)=C1 ZILBQSNRPDGJDC-UHFFFAOYSA-N 0.000 claims 1
- SVVQQZYYWOJAGA-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CNC1=NC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 SVVQQZYYWOJAGA-UHFFFAOYSA-N 0.000 claims 1
- PKRWFCLGWNBHBA-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)-3-(pyrrolidin-2-ylmethoxy)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CNC1=NC=CC=C1C(=O)NC1=CC=C(C(F)(F)C(F)(F)F)C(OCC2NCCC2)=C1 PKRWFCLGWNBHBA-UHFFFAOYSA-N 0.000 claims 1
- VIXCSVVABRZKOU-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CNC1=NC=CC=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 VIXCSVVABRZKOU-UHFFFAOYSA-N 0.000 claims 1
- LXKFMAUKOWWHOQ-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]-n-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(F)C=C1 LXKFMAUKOWWHOQ-UHFFFAOYSA-N 0.000 claims 1
- AQRDNYLHJOYURG-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)ethylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CCNC1=NC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 AQRDNYLHJOYURG-UHFFFAOYSA-N 0.000 claims 1
- NSPSEWFIMULCEX-UHFFFAOYSA-N 2-[[4-fluoro-3-(3-morpholin-4-ylprop-1-ynyl)phenyl]methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=C(C#CCN2CCOCC2)C(F)=CC=C1CNC1=NC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 NSPSEWFIMULCEX-UHFFFAOYSA-N 0.000 claims 1
- VEOYVWCLFQXJDN-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-3-[[3-[[4-(1,1,2,2,2-pentafluoroethyl)phenyl]carbamoyl]pyridin-2-yl]amino]propanoic acid Chemical compound C=1C=C2OCOC2=CC=1C(CC(=O)O)NC1=NC=CC=C1C(=O)NC1=CC=C(C(F)(F)C(F)(F)F)C=C1 VEOYVWCLFQXJDN-UHFFFAOYSA-N 0.000 claims 1
- WBDBXXMFTFNWOT-UHFFFAOYSA-N 3-(benzylamino)-n-(4-chlorophenyl)pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=NC=CC=C1NCC1=CC=CC=C1 WBDBXXMFTFNWOT-UHFFFAOYSA-N 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- WSYHESLLOFKCFE-UHFFFAOYSA-N 6-chloro-n-(4-chlorophenyl)-2-[(4-methoxyphenyl)methylamino]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC1=NC(Cl)=CC=C1C(=O)NC1=CC=C(Cl)C=C1 WSYHESLLOFKCFE-UHFFFAOYSA-N 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- OALHLMGXOLMLJK-UHFFFAOYSA-N C1=CC(OC)=CC=C1CNC1(C(=O)NC=2C=C(F)C(C)=CC=2)C=CC=CN1 Chemical compound C1=CC(OC)=CC=C1CNC1(C(=O)NC=2C=C(F)C(C)=CC=2)C=CC=CN1 OALHLMGXOLMLJK-UHFFFAOYSA-N 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000005466 alkylenyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000002474 dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 1
- MRTQFEVTVFYJKE-UHFFFAOYSA-N n-(2,2-dimethyl-3,4-dihydro-1,4-benzoxazin-6-yl)-2-[(4-fluorophenyl)methylamino]pyridine-3-carboxamide Chemical compound C=1C=C2OC(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=C(F)C=C1 MRTQFEVTVFYJKE-UHFFFAOYSA-N 0.000 claims 1
- RTNDAUSNQFJLJM-UHFFFAOYSA-N n-(3,3-dimethyl-1-piperidin-4-yl-2h-indol-6-yl)-2-[(4-fluorophenyl)methylamino]pyridine-3-carboxamide Chemical compound C12=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CC(F)=CC=3)=CC=C2C(C)(C)CN1C1CCNCC1 RTNDAUSNQFJLJM-UHFFFAOYSA-N 0.000 claims 1
- CCKNYUJCLRTAPN-UHFFFAOYSA-N n-(4,4-dimethyl-2-oxo-1,3-dihydroquinolin-7-yl)-2-[(4-fluorophenyl)methylamino]pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)CC(=O)NC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=C(F)C=C1 CCKNYUJCLRTAPN-UHFFFAOYSA-N 0.000 claims 1
- GGFBELLAMHBYAC-UHFFFAOYSA-N n-(4-acetyl-2,2-dimethyl-3h-1,4-benzoxazin-6-yl)-2-[(4-fluorophenyl)methylamino]pyridine-3-carboxamide Chemical compound C1=C2N(C(=O)C)CC(C)(C)OC2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(F)C=C1 GGFBELLAMHBYAC-UHFFFAOYSA-N 0.000 claims 1
- CBJQNTOIJSJSGJ-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-2-[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methylamino]pyridine-3-carboxamide Chemical compound C1=C(F)C(CCCN(C)C)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C(=CC(Br)=CC=2)F)=C1 CBJQNTOIJSJSGJ-UHFFFAOYSA-N 0.000 claims 1
- KEQYIGIJEUDESO-UHFFFAOYSA-N n-(4-chlorophenyl)-2-[(2-cyanophenyl)methylamino]pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=CC=C1C#N KEQYIGIJEUDESO-UHFFFAOYSA-N 0.000 claims 1
- UQEYWSCFQXQKOB-UHFFFAOYSA-N n-(4-chlorophenyl)-2-[(4-cyanophenyl)methylamino]pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(C#N)C=C1 UQEYWSCFQXQKOB-UHFFFAOYSA-N 0.000 claims 1
- UWOZEQLMJPPFRK-UHFFFAOYSA-N n-(4-chlorophenyl)-3-[(4-nitrophenyl)methylamino]pyridine-2-carboxamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1CNC1=CC=CN=C1C(=O)NC1=CC=C(Cl)C=C1 UWOZEQLMJPPFRK-UHFFFAOYSA-N 0.000 claims 1
- FUEGDGQHJRMBGX-UHFFFAOYSA-N n-(4-phenoxyphenyl)-n-[2-[[3-(trifluoromethyl)phenyl]methylamino]pyridin-3-yl]formamide Chemical compound FC(F)(F)C1=CC=CC(CNC=2C(=CC=CN=2)N(C=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 FUEGDGQHJRMBGX-UHFFFAOYSA-N 0.000 claims 1
- NHVOUMAHIHKFOA-UHFFFAOYSA-N n-(4-phenoxyphenyl)-n-[2-[[4-(trifluoromethoxy)phenyl]methylamino]pyridin-3-yl]formamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CNC1=NC=CC=C1N(C=O)C(C=C1)=CC=C1OC1=CC=CC=C1 NHVOUMAHIHKFOA-UHFFFAOYSA-N 0.000 claims 1
- XRVMPVGAKDAVEB-UHFFFAOYSA-N n-(4-phenoxyphenyl)-n-[2-[[4-(trifluoromethyl)phenyl]methylamino]pyridin-3-yl]formamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC1=NC=CC=C1N(C=O)C(C=C1)=CC=C1OC1=CC=CC=C1 XRVMPVGAKDAVEB-UHFFFAOYSA-N 0.000 claims 1
- XOEQGZQGQYFXCM-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methylamino]pyridine-3-carboxamide Chemical compound C1=C(F)C(CCCN(C)C)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=C1 XOEQGZQGQYFXCM-UHFFFAOYSA-N 0.000 claims 1
- FKISBQPOTDRBAG-UHFFFAOYSA-N n-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-[(4-fluorophenyl)methylamino]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC(CCCN(C)C)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CC(F)=CC=2)=C1 FKISBQPOTDRBAG-UHFFFAOYSA-N 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 150000003141 primary amines Chemical class 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- GQPUELDQOSKACF-UHFFFAOYSA-N tert-butyl 2-[[5-[[2-[(4-fluorophenyl)methylamino]pyridine-3-carbonyl]amino]-2-(1,1,2,2,2-pentafluoroethyl)phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CC(F)=CC=2)=CC=C1C(F)(F)C(F)(F)F GQPUELDQOSKACF-UHFFFAOYSA-N 0.000 claims 1
- RWGXNDGNHTUYSJ-UHFFFAOYSA-N tert-butyl 4-[[2-tert-butyl-5-[[2-[(4-fluorophenyl)methylamino]pyridine-3-carbonyl]amino]phenoxy]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CC(F)=CC=2)=CC=C1C(C)(C)C RWGXNDGNHTUYSJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26136001P | 2001-01-12 | 2001-01-12 | |
| US32368601P | 2001-09-19 | 2001-09-19 | |
| US10/046,526 US20020147198A1 (en) | 2001-01-12 | 2002-01-10 | Substituted arylamine derivatives and methods of use |
| PCT/US2002/000742 WO2002055501A2 (en) | 2001-01-12 | 2002-01-11 | N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004531473A JP2004531473A (ja) | 2004-10-14 |
| JP2004531473A5 true JP2004531473A5 (US06653308-20031125-C00057.png) | 2005-12-22 |
Family
ID=27366923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002556173A Withdrawn JP2004531473A (ja) | 2001-01-12 | 2002-01-11 | Ｎ−ピリジルカルボキサミド誘導体及びそれらを含有する医薬組成物 |
Country Status (7)
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| CA2440555A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| JP4343681B2 (ja) | 2001-05-08 | 2009-10-14 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | シアノアントラニルアミド誘導体およびそれらの薬剤としての使用 |
| GB2381750A (en) * | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
| US20040002604A1 (en) | 2001-12-10 | 2004-01-01 | Richard Apodaca | Phenylalkynes |
| AU2002351382A1 (en) * | 2001-12-13 | 2003-06-23 | Pharmacyclics, Inc. | Combination cancer therapy |
| NZ536504A (en) | 2002-05-24 | 2008-04-30 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| US7148357B2 (en) * | 2002-07-31 | 2006-12-12 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| MXPA04012948A (es) * | 2002-07-31 | 2005-09-12 | Schering Ag | Inhibidores antranilamidopiridinas vegfr-2 y vegfr-3. |
| US20040116479A1 (en) * | 2002-10-04 | 2004-06-17 | Fortuna Haviv | Method of inhibiting angiogenesis |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| PT1562940E (pt) | 2002-11-18 | 2007-07-23 | Chemocentryx Inc | Sulfonamidas de arilo. |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| BR0316971A (pt) * | 2002-12-02 | 2005-10-25 | Ortho Mcneil Pharm Inc | Fenilalquinas |
| TWI299664B (en) | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
| US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| AU2004249664A1 (en) * | 2003-05-19 | 2004-12-29 | Irm Llc | Immunosuppressant compounds and compositions |
| US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| US8309562B2 (en) * | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| TWI476206B (zh) | 2003-07-18 | 2015-03-11 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
| UA89035C2 (ru) * | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| NZ551602A (en) * | 2004-06-24 | 2010-11-26 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| DE602005024148D1 (de) * | 2004-08-25 | 2010-11-25 | Univ Chicago | Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma |
| EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| US7906533B2 (en) * | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| CA2587642C (en) | 2004-11-30 | 2013-04-09 | Amgen Inc. | Substituted heterocycles and methods of use |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US9109081B2 (en) * | 2005-02-16 | 2015-08-18 | Sumitomo Chemical Company, Limited | Method for producing aromatic polymer |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| EP1987023B1 (en) | 2006-02-10 | 2010-11-24 | Amgen, Inc | Hydrate forms of amg706 |
| TW200808807A (en) * | 2006-03-02 | 2008-02-16 | Incyte Corp | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| EP2118069B1 (en) | 2007-01-09 | 2014-01-01 | Amgen Inc. | Bis-aryl amide derivatives useful for the treatment of cancer |
| CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| WO2009020642A1 (en) * | 2007-08-09 | 2009-02-12 | Merck & Co., Inc. | Pyridine carboxamide orexin receptor antagonists |
| CL2008002444A1 (es) | 2007-08-21 | 2009-09-04 | Amgen Inc | Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente. |
| EP2202223B1 (en) | 2007-10-18 | 2017-01-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound as blood rbp4 lowering agent |
| US8350026B2 (en) | 2008-08-27 | 2013-01-08 | Leo Pharma A/S | VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| JP5706337B2 (ja) | 2009-04-16 | 2015-04-22 | 武田薬品工業株式会社 | （とりわけ）糖尿病の予防または治療に有用なｎ−アシル−ｎ’−フェニルピペラジンの誘導体 |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| CN103547566B (zh) | 2011-02-18 | 2017-05-31 | 阿萨纳生物科技有限责任公司 | 氨基茚满化合物及其治疗疼痛的用途 |
| EP2688887B1 (en) | 2011-03-23 | 2015-05-13 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| EP2714941A4 (en) * | 2011-05-24 | 2014-12-03 | Wistar Inst | COMPOSITIONS AND METHODS FOR MODULATING THE EFFECT OF THE EPSTEIN-BARR NUCLEAR ANTIGEN 1 |
| WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| SG11201406914XA (en) * | 2012-05-08 | 2014-11-27 | Anvyl Llc | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
| WO2014028675A1 (en) | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
| WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| CN105622499A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
| CA2972592A1 (en) | 2015-01-08 | 2016-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| EP3265445B1 (en) | 2015-03-06 | 2021-05-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| KR102594441B1 (ko) | 2015-03-06 | 2023-10-25 | 파마케아, 인크. | 플루오르화된 리실 옥시다아제-유사 2 억제제 및 이의 용도 |
| CN109983006B (zh) | 2016-09-07 | 2022-02-25 | 法玛克亚公司 | 赖氨酰氧化酶样2抑制剂的结晶形式及其制备方法 |
| CN117180280A (zh) | 2016-09-07 | 2023-12-08 | 法玛克亚公司 | 赖氨酰氧化酶样2抑制剂的用途 |
| MX2019007643A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibirores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal. |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP4403175A3 (en) | 2017-09-08 | 2024-10-02 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| AU2019262599B2 (en) | 2018-05-04 | 2023-10-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| EP3790886B1 (en) | 2018-05-10 | 2024-06-26 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| AU2019278998B2 (en) | 2018-06-01 | 2023-11-09 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| CA3099799A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| MX2021007157A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
| MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| CA3123227A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| CN113767100A (zh) | 2019-03-01 | 2021-12-07 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| KR20220011670A (ko) | 2019-05-21 | 2022-01-28 | 암젠 인크 | 고체 상태 형태 |
| WO2021007477A1 (en) | 2019-07-11 | 2021-01-14 | E-Scape Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| US20240254100A1 (en) | 2019-08-02 | 2024-08-01 | Amgen Inc. | Kif18a inhibitors |
| US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
| AU2020326627A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
| US20220281843A1 (en) | 2019-08-02 | 2022-09-08 | Amgen Inc. | Kif18a inhibitors |
| JP2022552873A (ja) | 2019-10-24 | 2022-12-20 | アムジエン・インコーポレーテツド | がんの治療におけるｋｒａｓ ｇ１２ｃ及びｋｒａｓ ｇ１２ｄ阻害剤として有用なピリドピリミジン誘導体 |
| US11739074B2 (en) | 2019-11-04 | 2023-08-29 | Revolution Medicines, Inc. | Ras inhibitors |
| AU2020379734A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| JP2023500328A (ja) | 2019-11-08 | 2023-01-05 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
| AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
| US20230192681A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| JP2023509701A (ja) | 2020-01-07 | 2023-03-09 | レヴォリューション・メディスンズ，インコーポレイテッド | Ｓｈｐ２阻害剤投薬およびがんを処置する方法 |
| CN111337620B (zh) * | 2020-05-09 | 2022-05-17 | 费森尤斯卡比华瑞制药有限公司 | 一种检测复方氨基酸注射液中3-氨基-2-哌啶酮含量的方法 |
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| AU2021345111A1 (en) | 2020-09-15 | 2023-04-06 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| RU2233273C3 (ru) * | 1999-09-16 | 2019-07-17 | Мицубиси Танабе Φαρμα Корпорейшн | Ароматические азотсодержащие 6-членные циклические соединения и фармацевтическая композиция |
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| DE10023492A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| PE20020870A1 (es) * | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas |
-
2002
- 2002-01-10 US US10/046,526 patent/US20020147198A1/en not_active Abandoned
- 2002-01-11 CA CA002434274A patent/CA2434274A1/en not_active Abandoned
- 2002-01-11 MX MXPA03006010A patent/MXPA03006010A/es unknown
- 2002-01-11 JP JP2002556173A patent/JP2004531473A/ja not_active Withdrawn
- 2002-01-11 WO PCT/US2002/000742 patent/WO2002055501A2/en active IP Right Grant
- 2002-01-11 EP EP02717324A patent/EP1358161A2/en not_active Withdrawn
- 2002-01-11 AU AU2002248339A patent/AU2002248339B2/en not_active Ceased
